The GLP-1 Revolution: How Obesity Drugs Are Reshaping Healthcare IB

Introduction

GLP-1 receptor agonists have transformed from a niche diabetes treatment into the most commercially significant drug class launched in the last two decades. Combined global revenue for semaglutide (Novo Nordisk's Ozempic and Wegovy) and tirzepatide (Eli Lilly's Mounjaro and Zepbound) reached approximately $63-70 billion in 2025, and consensus forecasts project the broader GLP-1/incretin market to reach $130-200 billion or more by 2030. For healthcare investment bankers, the GLP-1 story is not confined to a single therapeutic area or a single sub-sector. It is a cross-cutting force that is generating M&A activity, reshaping manufacturing economics, disrupting adjacent healthcare markets, and creating both massive winners and significant losers across the entire healthcare ecosystem.

The current GLP-1 market is dominated by two companies. Novo Nordisk's semaglutide franchise (Ozempic for diabetes, Wegovy for obesity) generated over $29 billion in 2025 revenue. Eli Lilly's tirzepatide franchise (Mounjaro for diabetes, Zepbound for obesity) is on a trajectory to reach comparable scale. Together, these two companies control approximately 90%+ of the global GLP-1 market.

GLP-1 Receptor Agonist

A class of drugs that mimic the glucagon-like peptide-1 (GLP-1) hormone, which stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on brain appetite centers to reduce food intake. Originally developed for type 2 diabetes, GLP-1 agonists demonstrated 15-25% body weight reduction in obesity trials, transforming them into blockbuster weight-loss therapies. Next-generation agents combine GLP-1 with other incretin targets (GIP, glucagon, amylin) to enhance efficacy.

The duopoly dynamic creates a specific competitive structure. Novo and Lilly compete primarily on efficacy (weight loss percentage), tolerability (GI side effects), and convenience (dosing frequency). Tirzepatide, a dual GIP/GLP-1 agonist, has shown modestly superior weight loss in head-to-head positioning, while semaglutide has a larger body of outcomes data, including the landmark SELECT cardiovascular outcomes trial that demonstrated a 20% reduction in major adverse cardiovascular events (MACE).

The commercial opportunity has attracted every major pharma company and dozens of clinical-stage biotechs. Over 50 GLP-1 and incretin-related candidates are in clinical development across multiple formats and mechanisms.

Oral GLP-1

Oral formulations of GLP-1 agonists that eliminate the need for injection, potentially expanding the addressable patient population significantly. Novo Nordisk's Rybelsus was the first oral GLP-1 approved (for diabetes), and both Novo and Lilly have oral obesity candidates in late-stage development. Oral formulations face bioavailability challenges (GLP-1 peptides are degraded in the GI tract), requiring absorption-enhancing technologies. The commercial thesis is that oral availability removes the injection barrier that limits uptake among the estimated 40%+ of eligible patients who decline injectable therapy.

The pipeline intensity is directly driving M&A. Pfizer's $10 billion acquisition of Metsera targeted long-acting injectable GLP-1 technology after Pfizer's internal oral program (danuglipron) experienced clinical setbacks. Novo Nordisk's $5.2 billion acquisition of Akero expanded beyond GLP-1 into MASH, a liver disease closely linked to metabolic dysfunction. Roche acquired Carmot Therapeutics for $2.7 billion (plus $400 million in milestones) to enter the GLP-1 space.

The GLP-1 revolution is generating M&A activity and strategic disruption across every healthcare sub-sector, not just biopharma.

CDMO manufacturing capacity. The most acute bottleneck in GLP-1 is manufacturing. Novo Nordisk's parent company acquired Catalent for **$16.5 billion** primarily to secure fill-finish capacity for semaglutide production. This transaction illustrates how modality-specific capacity constraints can drive CDMO valuations to strategic premiums far above standalone financial analysis. The GLP-1 manufacturing bottleneck has benefited every injectable CDMO with relevant capabilities, driving both organic growth and M&A premiums across the sector.

Healthcare services disruption. GLP-1 adoption is threatening established healthcare services verticals. Bariatric surgery volumes have declined in markets with high GLP-1 penetration. Sleep apnea device companies (ResMed, Philips) face demand erosion as weight loss reduces sleep apnea severity. Conversely, GLP-1 is creating demand for new services: obesity management clinics, metabolic health monitoring, and compounding pharmacies.

Medical device adjacency. Cardiovascular device companies face a complex GLP-1 dynamic. If GLP-1 drugs reduce cardiovascular events by 20%, long-term demand for stents, pacemakers, and heart failure devices could decline. However, the near-term effect may be positive: GLP-1 patients live longer, potentially increasing lifetime procedure volumes. Device companies like Abbott (continuous glucose monitors) and Dexcom are positioning CGM devices as GLP-1 companion diagnostics, creating a new revenue stream.

The GLP-1 market's trajectory from $63-70 billion today to $130-200 billion+ means it will remain the dominant theme in healthcare M&A for the foreseeable future. Every healthcare banker, regardless of sub-sector focus, needs a working understanding of the competitive dynamics, pipeline threats, and cross-sector implications.

The next article covers AI in healthcare, examining how artificial intelligence is moving from conference-deck hype to clinical pipeline reality.